|
PROSTATE CANCER/BRAIN CANCER SUSCEPTIBILITY (finding)
|
0.400 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Adenocarcinoma of prostate
|
0.300 |
CausalMutation
|
disease |
CGI |
|
|
|
|
PROSTATE CANCER/BRAIN CANCER SUSCEPTIBILITY (finding)
|
0.400 |
SusceptibilityMutation
|
disease |
CLINVAR |
|
|
|
|
Prostate cancer, familial
|
0.310 |
SusceptibilityMutation
|
disease |
ORPHANET |
A common nonsense mutation in EphB2 is associated with prostate cancer risk in African American men with a positive family history.
|
16155194 |
2006 |
|
Malignant neoplasm of prostate
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Collectively, these results show that MAPK pathways ERK, JNK/SAPK, and P38-MAPK represent a significant component in the regulation of u-PA expression in human CaP.
|
11676474 |
2001 |
|
Malignant neoplasm of prostate
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
FOXO3a Expression Regulated by ERK Signaling is Inversely Correlated With Y-Box Binding Protein-1 Expression in Prostate Cancer.
|
27699813 |
2017 |
|
Malignant neoplasm of prostate
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of lncRNA-ATB exerts mitogenic and EMT effects of prostate cancer via activation of ERK and PI3K/AKT signaling pathways.
|
27176634 |
2016 |
|
Malignant neoplasm of prostate
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Taken together with studies indicating that EphB2 may have an essential role in cell migration and maintenance of normal tissue architecture, our findings suggest that mutational inactivation of EPHB2 may be important in the progression and metastasis of prostate cancer.
|
15300251 |
2004 |
|
Malignant neoplasm of prostate
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
ERK and AKT signaling drive MED1 overexpression in prostate cancer in association with elevated proliferation and tumorigenicity.
|
23538858 |
2013 |
|
Malignant neoplasm of prostate
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
With inhibition of p38, ERK, and JNK, the TSP-2-induced cell migration and MMP-2 expression were abolished, indicating that the TSP-2's effect on PCa is MAPK dependent.
|
28122633 |
2017 |
|
Malignant neoplasm of prostate
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
MEK/ERK inhibitors are also in clinical trials and the importance of pRB inactivation in prostate cancer is becoming more widely recognized.
|
25070358 |
2014 |
|
Malignant neoplasm of prostate
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
We have found that the nuclear ERK-selective phosphatase DUSP5 is downregulated in colorectal tumours and cell lines, as previously observed in gastric and prostate cancer.
|
29379130 |
2018 |
|
Malignant neoplasm of prostate
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that aberrant loss of MAPK/ERK activity in prostate cancer may play a pivotal role in the malignant phenotype, and provide evidence that interventions aimed at bypassing the signaling block are able to effectively reverse neoplastic unchecked cell proliferation.
|
17143532 |
2007 |
|
Malignant neoplasm of prostate
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The upregulation of parts of the EphB2 and Src pathways also predicts poor prognosis in the prostate cancer patient cohort of The Cancer Genome Atlas.
|
31805710 |
2019 |
|
Malignant neoplasm of prostate
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Finally, the results demonstrated that AQP3 upregulated matrix metalloproteinase‑3 (MMP‑3) expression and secretion in prostate cancer cells via activation of the ERK pathway.
|
25515250 |
2015 |
|
Colorectal Neoplasms
|
0.190 |
AlteredExpression
|
group |
BEFREE |
The receptor tyrosine kinase EphB2 is expressed by colon progenitor cells; however, only 39% of colorectal tumors express EphB2 and expression levels decline with disease progression.
|
19366806 |
2009 |
|
Colorectal Neoplasms
|
0.190 |
AlteredExpression
|
group |
LHGDN |
Overexpression of EphA4 gene and reduced expression of EphB2 gene correlates with liver metastasis in colorectal cancer.
|
18695888 |
2008 |
|
Colorectal Neoplasms
|
0.190 |
AlteredExpression
|
group |
LHGDN |
EphB receptor activity suppresses colorectal cancer progression.
|
15973414 |
2005 |
|
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Increasing EphB2 levels or function could be beneficial in Alzheimer's disease.
|
21113149 |
2011 |
|
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we find that activation of endogenous EphB2 receptor by ligand stimulation (ephrinB1/Fc) or by ectopic expression of EphB2 plus the ligand stimulation induces a remarkable tau dephosphorylation at multiple AD-associated sites in SK-N-SH cells and human embryonic kidney cells that stably express human tau (HEK293-tau).
|
26119563 |
2015 |
|
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Putting all the pieces of experimental evidence together, we hypothesize that tramadol might alleviate AD pathological hallmarks at least in cellular level through decreasing activity of PI3K-AKT and ERK and also mTOR signaling pathways respectively and results in autophagy activation as well as tau-dephosphorylation.
|
29317054 |
2018 |
|
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results provide evidence of the different expression profiles and function of EphB2 between astrocytes and neurons in AD pathology.
|
30899407 |
2019 |
|
Alzheimer's Disease
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Significant genes and pathways were identified from the bioinformatics analyses - in particular ERK/MAPK signaling, up-regulated in GBM and Angiopoietin Signaling pathway, reciprocally up-regulated in AD - connecting GBM and AD (P < 0.001), were investigated in details for their roles in GBM growth in an AD environment.
|
24322672 |
2013 |
|
Rheumatoid Arthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Taken together, our results indicated that Dyrk1A might promote FLSs proliferation, migration and invasion by suppressing Spry2 expression and activating the ERK MAPK signaling pathway in RA.
|
30503061 |
2018 |
|
Rheumatoid Arthritis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MEK-ERK pathway is a negative regulator of GDF-5 expression in FLS-RA.
|
19818765 |
2010 |